GeneDx CEO Sells Over $2.9M in Stock

Insider selling transaction represents a 33.90% decrease in CEO's ownership stake.

Apr. 5, 2026 at 8:34am

Got story updates? Submit your updates here. ›

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,933 shares of the company's stock in a transaction on March 26th, 2026. The shares were sold at an average price of $63.17, resulting in a total transaction value of $2,964,757.61. Following the sale, Stueland now owns 91,514 shares in the company, valued at approximately $5,780,939.38.

Why it matters

Insider selling transactions can provide insight into a company's leadership's views on the stock's valuation and future prospects. This significant sale by the CEO represents a 33.90% decrease in her ownership stake, which may signal concerns about GeneDx's outlook.

The details

The transaction was disclosed in a filing with the SEC. Stueland has made several other recent trades in GeneDx stock. The company's shares have traded in a 52-week range of $55.17 to $170.87, with a current market cap of $1.94 billion.

  • The stock sale transaction occurred on March 26, 2026.

The players

Katherine Stueland

CEO of GeneDx Holdings Corp.

GeneDx Holdings Corp.

A clinical diagnostics company specializing in genetic and genomic testing for rare and inherited disorders.

Got photos? Submit your photos here. ›

What they’re saying

“The trade was a 33.90% decrease in their ownership of the stock.”

— Katherine Stueland, CEO

What’s next

Investors will likely continue to monitor GeneDx's stock performance and any further insider trading activity by the CEO and other company executives.

The takeaway

This significant insider sale by the GeneDx CEO raises questions about the company's future prospects and may signal concerns about the stock's valuation from company leadership.